FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503) 10903 New Hampshire Avenue, Silver Spring, Maryland December 14, 2015

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Stephanie L. Begansky, PharmD

Division of Advisory Committee and Consultant Management Office of Executive Programs, CDER, FDA

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Daniel Budnitz, MD, MPH

CAPT, US Public Health Service Director, Medication Safety Program Division of Healthcare Quality Promotion Centers for Disease Control and Prevention Atlanta, Georgia

Diana Hallare, MPH

(Consumer Representative) Visalia, California

William R. Hiatt, MD, FACP, FAHA

(via telephone)
Professor of Medicine/Cardiology
University of Colorado School of Medicine
President, CPC
Aurora, Colorado

Brendan M. Everett, MD, MPH

Assistant Professor of Medicine Harvard Medical School Director, General Cardiology Inpatient Service Brigham and Women's Hospital Boston, Massachusetts

Susan R. Heckbert, MD, PhD

Professor Department of Epidemiology University of Washington Cardiovascular Health Research Unit Seattle, Washington

Robert J. Smith, MD

(Chairperson)
Professor of Medicine (Endocrinology)
Alpert Medical School of Brown University
Professor of Health Services, Policy and Practice
Brown School of Public Health
Research Staff, Ocean State Research Institute
Providence Veterans Administration (VA) Medical
Center
Providence, Rhode Island

Peter W. F. Wilson, MD

Director
Epidemiology and Genomic Medicine
Atlanta Veterans Administration Medical Center
Professor of Medicine and Public Health
Emory University
Emory Clinical Cardiovascular Research Institute
Atlanta, Georgia

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting December 14, 2015

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Michael J. Blaha, MD, MPH

Assistant Professor Cardiology and Epidemiology Director of Clinical Research Ciccarone Center for the Prevention of Heart Disease Johns Hopkins Hospital Baltimore, Maryland

Seattle, Washington

Thomas R. Fleming, PhD

University of Washington

Professor, Department of Biostatistics

Sanjay Kaul, MD

Professor UCLA School of Medicine Attending Cardiologist Cedars-Sinai Medical Center Los Angeles, California

Debra McCall, MBA

(Patient Representative) Murrieta, California

Milton Packer, MD

Distinguished Scholar in Cardiovascular Science Baylor University Medical Center Dallas, Texas

Michael Proschan, PhD

Mathematical Statistician Biostatistics Research Branch National Institute of Allergy and Infectious Diseases National Institutes of Health (NIH) Bethesda, Maryland

Robert D. Shamburek, MD

Clinician/Scientist
Lipoprotein Metabolism Section
Cardiovascular and Pulmonary Branch
NHLBI, NIH
Bethesda, Maryland

John R. Teerlink, MD

Director, Heart Failure
Director, Echocardiography
San Francisco Veterans Affairs Medical Center
Professor of Medicine
School of Medicine
University of California San Francisco
San Francisco, California

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Reshma Kewalramani, MD

(Acting Industry Representative)
Vice President
US Medical Organization
Amgen
Thousand Oaks, California

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting December 14, 2015

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Curtis J. Rosebraugh, MD, MPH

Director

Office of Drug Evaluation II (ODE II)
Office of New Drugs (OND), CDER, FDA

James P. Smith, MD, MS

Deputy Director DMEP, ODE II, OND, CDER, FDA

Jennifer Clark, PhD

Mathematical Statistician
Division of Biometrics (DB) II
Office of Biostatistics (OB)
Office of Translational Sciences (OTS)
CDER, FDA

Jean-Marc Guettier, MD

Director

Division of Metabolism and Endocrinology Products (DMEP)

ODE II, OND, CDER, FDA

Iffat Nasrin Chowdhury, MD

Medical Officer DMEP, ODE II, OND, CDER, FDA